Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Sphingosine kinase 2 restricts T cell immunopathology but permits viral persistence
Caleb J. Studstill, … , Sang-Myeong Lee, Bumsuk Hahm
Caleb J. Studstill, … , Sang-Myeong Lee, Bumsuk Hahm
Published September 8, 2020
Citation Information: J Clin Invest. 2020;130(12):6523-6538. https://doi.org/10.1172/JCI125297.
View: Text | PDF
Research Article Immunology Virology Article has an altmetric score of 56

Sphingosine kinase 2 restricts T cell immunopathology but permits viral persistence

  • Text
  • PDF
Abstract

Chronic viral infections are often established by the exploitation of immune-regulatory mechanisms that result in nonfunctional T cell responses. Viruses that establish persistent infections remain a serious threat to human health. Sphingosine kinase 2 (SphK2) generates sphingosine 1-phosphate, which is a molecule known to regulate multiple cellular processes. However, little is known about SphK2’s role during the host immune responses to viral infection. Here, we demonstrate that SphK2 functions during lymphocytic choriomeningitis virus Cl 13 (LCMV Cl 13) infection to limit T cell immune pathology, which subsequently aids in the establishment of virus-induced immunosuppression and the resultant viral persistence. The infection of Sphk2-deficient (Sphk2–/–) mice with LCMV Cl 13 led to the development of nephropathy and mortality via T cell–mediated immunopathology. Following LCMV infection, Sphk2–/– CD4+ T cells displayed increased activity and proliferation, and these cells promoted overactive LCMV Cl 13–specific CD8+ T cell responses. Notably, oral instillation of an SphK2-selective inhibitor promoted protective T cell responses and accelerated the termination of LCMV Cl 13 persistence in mice. Thus, SphK2 is indicated as an immunotherapeutic target for the control of persistent viral infections.

Authors

Caleb J. Studstill, Curtis J. Pritzl, Young-Jin Seo, Dae Young Kim, Chuan Xia, Jennifer J. Wolf, Ravi Nistala, Madhuvanthi Vijayan, Yong-Bin Cho, Kyung Won Kang, Sang-Myeong Lee, Bumsuk Hahm

×

Figure 3

CD4+ T cell responses against LCMV Cl 13 are required for SphK2 deficiency–mediated mortality.

Options: View larger image (or click on image) Download as PowerPoint
CD4+ T cell responses against LCMV Cl 13 are required for SphK2 deficien...
(A–E) WT or Sphk2–/– mice (n = 3–4 mice/group) were infected with LCMV Cl 13. (A) Number of LCMV GP66 (GP66-77) tetramer+ CD4+ T cells, (B) number of IFN-γ+ GP61 (GP61-80)–specific CD4+ T cells out of total CD4+ T cells, (C) number of IL-2+ GP61-specific CD4+ T cells out of total CD4+ T cells, and (D) number of Ki67+ CD4+ T cells in the spleen were assessed at 7 dpi by flow cytometry. (E) Percentage of GP66 tetramer+CD4+ T cells in the livers were also assessed at 7 dpi. (F) Survival rate of Sphk2–/– mice after depletion (αCD4 + LCMV Cl 13) or no depletion (LCMV Cl 13) of CD4+ T cells (n = 5 mice/group) is depicted. *P ≤ 0.05; **P ≤ 0.01, bidirectional, unpaired Student’s t test. Data are representative of 2–3 independent experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 7 news outlets
Posted by 10 X users
Referenced in 4 patents
14 readers on Mendeley
See more details